A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03855358

Recruitment Status : Unknown

Verified February 2019 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd..
Recruitment status was: Recruiting

First Posted : February 26, 2019

Last Update Posted : October 30, 2019

Sponsor:

Information provided by (Responsible Party):

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Study Details
Tabular View
No Results Posted
Disclaimer
How to Read a Study Record

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Unknown
Estimated Primary Completion Date :	June 30, 2020
Estimated Study Completion Date :	December 30, 2020

To Top